149 related articles for article (PubMed ID: 34128111)
1. Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
Adachi JI; Shirahata M; Suzuki T; Mishima K; Uchida E; Sasaki A; Nishikawa R
Brain Tumor Pathol; 2021 Jul; 38(3):201-209. PubMed ID: 34128111
[TBL] [Abstract][Full Text] [Related]
2. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H
Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624
[TBL] [Abstract][Full Text] [Related]
3. Advances in Detecting Low Prevalence Somatic
da Costa VR; Bim LV; Pacheco E Silva LDP; Colloza-Gama GA; Bastos AU; Delcelo R; Oler G; Cerutti JM
Front Endocrinol (Lausanne); 2021; 12():643151. PubMed ID: 33776938
[TBL] [Abstract][Full Text] [Related]
4. Highly sensitive detection of TERT promoter mutations in recurrent glioblastomas using digital PCR.
Miki S; Satomi K; Ohno M; Matsushita Y; Kitahara M; Miyakita Y; Takahashi M; Matsuda M; Ishikawa E; Matsumura A; Yoshida A; Narita Y; Ichimura K
Brain Tumor Pathol; 2020 Oct; 37(4):154-158. PubMed ID: 32749624
[TBL] [Abstract][Full Text] [Related]
5.
Muralidharan K; Yekula A; Small JL; Rosh ZS; Kang KM; Wang L; Lau S; Zhang H; Lee H; Bettegowda C; Chicoine MR; Kalkanis SN; Shankar GM; Nahed BV; Curry WT; Jones PS; Cahill DP; Balaj L; Carter BS
Clin Cancer Res; 2021 Jan; 27(1):169-178. PubMed ID: 33051308
[TBL] [Abstract][Full Text] [Related]
6. Spatial Distribution Patterns of Clinically Relevant TERT Promoter Mutations in Follicular Thyroid Tumors of Uncertain Malignant Potential: Advantages of the Digital Droplet PCR Technique.
Hysek M; Jatta K; Hellgren LS; Stenman A; Larsson C; Zedenius J; Juhlin CC
J Mol Diagn; 2021 Feb; 23(2):212-222. PubMed ID: 33197629
[TBL] [Abstract][Full Text] [Related]
7. Development of Novel Mutation-Specific Droplet Digital PCR Assays Detecting TERT Promoter Mutations in Tumor and Plasma Samples.
Corless BC; Chang GA; Cooper S; Syeda MM; Shao Y; Osman I; Karlin-Neumann G; Polsky D
J Mol Diagn; 2019 Mar; 21(2):274-285. PubMed ID: 30827467
[TBL] [Abstract][Full Text] [Related]
8. Establishment and Validation of the Detection of TERT Promoter Mutations by Human Gliomas U251 Cell Lines.
Bai H; Bai S; Li X; Zhang Y; Li Y; He F; Cheng W
Biomed Res Int; 2021; 2021():3271395. PubMed ID: 34159191
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutation detection by droplet digital PCR in glioma.
Wang J; Zhao YY; Li JF; Guo CC; Chen FR; Su HK; Zhao HF; Long YK; Shao JY; To Ss; Chen ZP
Oncotarget; 2015 Nov; 6(37):39651-60. PubMed ID: 26485760
[TBL] [Abstract][Full Text] [Related]
10. The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR.
Liu J; Zhao Z; Sun M; Chen K; Yuan W; Jiang G
Genet Test Mol Biomarkers; 2016 Feb; 20(2):90-3. PubMed ID: 26741813
[TBL] [Abstract][Full Text] [Related]
11. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
12. Distinct TERT promoter C228T and C250T mutations in a patient with an oligodendroglioma: A case report.
Ishi Y; Okada H; Okamoto M; Motegi H; Tanaka S; Mitsuhashi T; Yamaguchi S
Neuropathology; 2021 Jun; 41(3):236-242. PubMed ID: 33899270
[TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid.
Fujioka Y; Hata N; Akagi Y; Kuga D; Hatae R; Sangatsuda Y; Michiwaki Y; Amemiya T; Takigawa K; Funakoshi Y; Sako A; Iwaki T; Iihara K; Mizoguchi M
J Neurooncol; 2021 Mar; 152(1):47-54. PubMed ID: 33417137
[TBL] [Abstract][Full Text] [Related]
15. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
16. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors.
Dubbink HJ; Bakels H; Post E; Zwarthoff EC; Verdijk RM
J Neurooncol; 2014 Nov; 120(2):267-72. PubMed ID: 25035100
[TBL] [Abstract][Full Text] [Related]
18. Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
Ge J; Liu MY; Li L; Deng Q; Liu F; Luo Y; Wang L; Yao G; Zhu D; Lu H; Liang M; Deng S; Zhou R; Luo T
Int J Clin Exp Pathol; 2020; 13(2):230-238. PubMed ID: 32211103
[TBL] [Abstract][Full Text] [Related]
19. Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing.
McEvoy AC; Wood BA; Ardakani NM; Pereira MR; Pearce R; Cowell L; Robinson C; Grieu-Iacopetta F; Spicer AJ; Amanuel B; Ziman M; Gray ES
J Mol Diagn; 2018 Mar; 20(2):240-252. PubMed ID: 29305225
[TBL] [Abstract][Full Text] [Related]
20. TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
Hewer E; Phour J; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
J Neuropathol Exp Neurol; 2020 Apr; 79(4):430-436. PubMed ID: 32068851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
